Company Filing History:
Years Active: 2016-2025
Title: Frédéric Mourlane: Innovator in Immunotherapy
Introduction
Frédéric Mourlane is a notable inventor based in Nice, France. He has made significant contributions to the field of immunotherapy, particularly through his innovative patent work. With a total of 4 patents, Mourlane's inventions focus on enhancing the efficacy and control of chimeric antigen receptor (CAR) therapies.
Latest Patents
One of Mourlane's latest patents is the "Aptamer-based CAR T-cell switch." This technology provides an advanced method for controlling CAR-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule that connects a target-binding aptamer to a CAR-binding aptamer. This system allows for targeted immunotherapy, enabling customization to any desired antigen and the ability to switch targets as needed. It also offers the flexibility to adjust dosages according to individual patient requirements and can be integrated with both in vivo and ex vivo CAR expression.
Another significant patent involves "Viral vector constructs for expression of genetic adjuvants activating the CD40 and STING pathways." These viral vectors serve as genetic immunotherapeutic agents, useful for both preventive and therapeutic vaccines. They enhance cellular and innate immune responses, particularly in the treatment of cancer and infectious diseases. The vectors include lentiviral constructs that encode various antigens and adjuvants, optimizing them for human expression.
Career Highlights
Throughout his career, Mourlane has worked with various companies, including Alaya.bio Inc. His work has been instrumental in advancing the field of immunotherapy, showcasing his commitment to innovative solutions in medicine.
Collaborations
Mourlane has collaborated with notable professionals in his field, including Cécile Bauche and Renaud Vaillant. These partnerships have contributed to the development and refinement of his groundbreaking technologies.
Conclusion
Frédéric Mourlane stands out as a pioneering inventor in the realm of immunotherapy. His innovative patents reflect a deep understanding of the complexities of immune responses and the potential for targeted therapies. His contributions are paving the way for future advancements in medical treatments.